Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000117696 | SCV000151943 | uncertain significance | not provided | 2014-02-03 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000117696 | SCV000704822 | uncertain significance | not provided | 2017-01-04 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001854569 | SCV002208733 | uncertain significance | Myofibrillar myopathy 3 | 2021-08-29 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The threonine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. ClinVar contains an entry for this variant (Variation ID: 129682). This variant has not been reported in the literature in individuals affected with MYOT-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces isoleucine with threonine at codon 41 of the MYOT protein (p.Ile41Thr). The isoleucine residue is weakly conserved and there is a moderate physicochemical difference between isoleucine and threonine. |